Affimed Research and Development Expenses 2014-2024 | AFMDQ
Affimed research and development expenses from 2014 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Affimed Annual Research and Development Expenses
(Millions of US $) |
| 2023 |
$103 |
| 2022 |
$104 |
| 2021 |
$96 |
| 2020 |
$57 |
| 2019 |
$49 |
| 2018 |
$42 |
| 2017 |
$24 |
| 2016 |
$33 |
| 2015 |
$24 |
| 2014 |
$13 |
| 2013 |
$0 |
| 2012 |
$0 |
Affimed Quarterly Research and Development Expenses
(Millions of US $) |
| 2024-09-30 |
$11 |
| 2024-06-30 |
$13 |
| 2024-03-31 |
$17 |
| 2023-12-31 |
$20 |
| 2023-09-30 |
$23 |
| 2023-06-30 |
$28 |
| 2023-03-31 |
$32 |
| 2022-12-31 |
$35 |
| 2022-09-30 |
$26 |
| 2022-06-30 |
$22 |
| 2022-03-31 |
$21 |
| 2021-12-31 |
$32 |
| 2021-09-30 |
$24 |
| 2021-06-30 |
$26 |
| 2021-03-31 |
$14 |
| 2020-12-31 |
$20 |
| 2020-09-30 |
$12 |
| 2020-06-30 |
$13 |
| 2020-03-31 |
$13 |
| 2019-12-31 |
$14 |
| 2019-09-30 |
$13 |
| 2019-06-30 |
$13 |
| 2019-03-31 |
$9 |
| 2018-12-31 |
$14 |
| 2018-09-30 |
$11 |
| 2018-06-30 |
$9 |
| 2018-03-31 |
$8 |
| 2017-12-31 |
$5 |
| 2017-09-30 |
$7 |
| 2017-06-30 |
$6 |
| 2017-03-31 |
$6 |
| 2016-12-31 |
$6 |
| 2016-09-30 |
$10 |
| 2016-06-30 |
$10 |
| 2016-03-31 |
$8 |
| 2015-12-31 |
$8 |
| 2015-09-30 |
$7 |
| 2015-06-30 |
$6 |
| 2015-03-31 |
$3 |
| 2014-12-31 |
|
| 2014-09-30 |
$3 |
| 2014-06-30 |
|
| 2014-03-31 |
|
| 2013-09-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
